Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1985 1
1987 1
1989 1
1990 2
1994 1
1995 4
1996 3
1997 3
1998 4
1999 14
2000 8
2001 13
2002 18
2003 24
2004 23
2005 15
2006 22
2007 17
2008 23
2009 24
2010 23
2011 22
2012 21
2013 23
2014 7
2015 14
2016 12
2017 8
2018 8
2019 9
2020 11
2021 12
2022 14
2023 7
2024 5
2025 12
2026 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

388 results

Results by year

Filters applied: . Clear all
Page 1
Mirtazapine as Appetite Stimulant in Patients With Non-Small Cell Lung Cancer and Anorexia: A Randomized Clinical Trial.
Arrieta O, Cárdenas-Fernández D, Rodriguez-Mayoral O, Gutierrez-Torres S, Castañares D, Flores-Estrada D, Reyes E, López D, Barragán P, Soberanis Pina P, Cardona AF, Turcott JG. Arrieta O, et al. JAMA Oncol. 2024 Mar 1;10(3):305-314. doi: 10.1001/jamaoncol.2023.5232. JAMA Oncol. 2024. PMID: 38206631 Free PMC article. Clinical Trial.
IMPORTANCE: Currently there is no standard therapy to improve cancer-related anorexia, hampering survival. Mirtazapine has been suggested as a feasible option in this context. OBJECTIVES: To assess the effect of mirtazapine on appetite and energy consumption in pati …
IMPORTANCE: Currently there is no standard therapy to improve cancer-related anorexia, hampering survival. Mirtazapine has been sugge …
Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design.
Rush AJ, Fava M, Wisniewski SR, Lavori PW, Trivedi MH, Sackeim HA, Thase ME, Nierenberg AA, Quitkin FM, Kashner TM, Kupfer DJ, Rosenbaum JF, Alpert J, Stewart JW, McGrath PJ, Biggs MM, Shores-Wilson K, Lebowitz BD, Ritz L, Niederehe G; STAR*D Investigators Group. Rush AJ, et al. Control Clin Trials. 2004 Feb;25(1):119-42. doi: 10.1016/s0197-2456(03)00112-0. Control Clin Trials. 2004. PMID: 15061154 Clinical Trial.
Level 2 and 2A participants are eligible for random assignment to two switch options (mirtazapine or nortriptyline) and to two augment options (lithium or thyroid hormone) added to the primary antidepressant (citalopram, bupropion, sertraline, or venlafaxine) (level 3). Th …
Level 2 and 2A participants are eligible for random assignment to two switch options (mirtazapine or nortriptyline) and to two augmen …
Mirtazapine for chronic insomnia in older adults: a randomised double-blind placebo-controlled trial-the MIRAGE study.
Nguyen PV, Dang-Vu TT, Forest G, Desjardins S, Forget MF, Vu TT, Nguyen QD, Kouassi E, Desmarais P. Nguyen PV, et al. Age Ageing. 2025 Mar 3;54(3):afaf050. doi: 10.1093/ageing/afaf050. Age Ageing. 2025. PMID: 40135470 Free article. Clinical Trial.
BACKGROUND: Mirtazapine promotes sleep by blocking serotonin and histaminergic receptors and is often used off-label to treat chronic insomnia. ...Despite the current lack of robust evidence, mirtazapine is widely prescribed by clinicians to treat insomnia in older …
BACKGROUND: Mirtazapine promotes sleep by blocking serotonin and histaminergic receptors and is often used off-label to treat chronic …
Mirtazapine for Methamphetamine Use Disorder: A Randomized Clinical Trial.
McKetin R, Shoptaw S, Saunders L, Nguyen L, Clare PJ, Dore GJ, Turner A, Dean OM, Kelly PJ, Arunogiri S, Koeijers J, Degan TJ, Degenhardt L, Farrell M, Goodman-Meza D, Sinclair B, Reid D, Cordaro F, Hill H, Lundin R, Hayllar J, Christmass M, Liaw W, Liu D, Woods A, Brewerton B, Holyoak E, Wu BT, Maher H, O'Dea N, Keygan J, Kontogiannis A, Palmer L, Morrison C, Wrobel A, Hyland B, Kiden G, Romeo V, Kyaw KWY, Byrne M, Colledge-Frisby S, Zahra E, Berk M. McKetin R, et al. JAMA Psychiatry. 2026 Jun 1;83(6):581-589. doi: 10.1001/jamapsychiatry.2026.0159. JAMA Psychiatry. 2026. PMID: 41920558 Free PMC article. Clinical Trial.
More participants in the mirtazapine group reported drowsiness (47% vs 33%) and weight gain (10% vs 3%). Forty participants (23%) discontinued mirtazapine due to adverse events compared to 25 participants (15%) in the placebo group. No significant effects of mirt …
More participants in the mirtazapine group reported drowsiness (47% vs 33%) and weight gain (10% vs 3%). Forty participants (23%) dis …
Maintenance or Discontinuation of Antidepressants in Primary Care.
Lewis G, Marston L, Duffy L, Freemantle N, Gilbody S, Hunter R, Kendrick T, Kessler D, Mangin D, King M, Lanham P, Moore M, Nazareth I, Wiles N, Bacon F, Bird M, Brabyn S, Burns A, Clarke CS, Hunt A, Pervin J, Lewis G. Lewis G, et al. N Engl J Med. 2021 Sep 30;385(14):1257-1267. doi: 10.1056/NEJMoa2106356. N Engl J Med. 2021. PMID: 34587384 Clinical Trial.
Patients who had received citalopram, fluoxetine, sertraline, or mirtazapine were randomly assigned in a 1:1 ratio to maintain their current antidepressant therapy (maintenance group) or to taper and discontinue such therapy with the use of matching placebo (discontinuatio …
Patients who had received citalopram, fluoxetine, sertraline, or mirtazapine were randomly assigned in a 1:1 ratio to maintain their …
Mirtazapine or ondansetron for hyperemesis gravidarum: a randomized placebo-controlled trial.
Ostenfeld A, Carlsen SE, Jensen AK, Futtrup TB, Westergaard HB, Pedersen LH, Andersen JT, Petersen TS, Løkkegaard ECL; VOMIT investigation group. Ostenfeld A, et al. Am J Obstet Gynecol. 2026 Jun;234(6):1700-1729. doi: 10.1016/j.ajog.2025.12.061. Epub 2025 Dec 30. Am J Obstet Gynecol. 2026. PMID: 41478546 Free article. Clinical Trial.
The differences in Pregnancy Unique Quantification of Emesis 24 score change in mirtazapine vs both ondansetron and placebo were more evident after day 4. All analyses regarding symptom severity showed a tendency toward mirtazapine being a more effective treatment t …
The differences in Pregnancy Unique Quantification of Emesis 24 score change in mirtazapine vs both ondansetron and placebo were more …
Effectiveness of low-dose amitriptyline and mirtazapine in patients with insomnia disorder and sleep maintenance problems: a randomised, double-blind, placebo-controlled trial in general practice (DREAMING).
Bakker MH, Hugtenburg JG, Bet PM, Twisk JW, van der Horst HE, Slottje P. Bakker MH, et al. Br J Gen Pract. 2025 Jun 26;75(756):e474-e483. doi: 10.3399/BJGP.2024.0173. Print 2025 Jul. Br J Gen Pract. 2025. PMID: 39814428 Free PMC article. Clinical Trial.
At 6 weeks, in the intention-to-treat analyses, mirtazapine and amitriptyline each led to statistically significantly lower ISI scores when compared with placebo: mirtazapine mean difference = -6.0 points (95% confidence interval [CI] = -9.0 to -3.0), amitriptyline …
At 6 weeks, in the intention-to-treat analyses, mirtazapine and amitriptyline each led to statistically significantly lower ISI score …
Mirtazapine versus megestrol acetate in treatment of anorexia-cachexia in advanced cancer patients: a randomized, double-blind trial.
Chowdhury IH, Rahman MS, Chowdhury MNK, Afroze YJ, Tabassum M, Marnush M, Zerin N. Chowdhury IH, et al. Jpn J Clin Oncol. 2024 May 7;54(5):530-536. doi: 10.1093/jjco/hyae009. Jpn J Clin Oncol. 2024. PMID: 38323684 Free article. Clinical Trial.
This study is considered to find out whether there is any role of mirtazapine in the improvement of anorexia in cancer patients. METHODS: A total of 80 cancer-anorexia patients were enrolled. Patients in the trial arm received the standard chemotherapy medication plus one …
This study is considered to find out whether there is any role of mirtazapine in the improvement of anorexia in cancer patients. METH …
Effect of combination therapy of methylfolate with antidepressants in patients with depressive disorder.
Siddique A, Khokhar MM, Waheed A, Naeem U, Aziz SA. Siddique A, et al. BMC Pharmacol Toxicol. 2025 Jan 22;26(1):14. doi: 10.1186/s40360-025-00846-x. BMC Pharmacol Toxicol. 2025. PMID: 39844190 Free PMC article. Clinical Trial.
METHODS: In an open-label clinical trial, forty-four patients with depressive disorder (6A70, 6A71, and 6A72 according to ICD-11) received an evidence-based antidepressant therapy (either escitalopram 10-20 mg, sertraline 50-100 mg, fluoxetine 20-40 mg, duloxetine 30-60 mg, mi …
METHODS: In an open-label clinical trial, forty-four patients with depressive disorder (6A70, 6A71, and 6A72 according to ICD-11) received a …
Mirtazapine reduces hypothetical methamphetamine demand in humans.
Rush CR, Santos GM, McMahan VM, Fraser A, Clark J, Luna Marti X, Walker JE, Shoptaw S, Coffin PO. Rush CR, et al. Drug Alcohol Depend. 2025 Sep 1;274:112769. doi: 10.1016/j.drugalcdep.2025.112769. Epub 2025 Jun 24. Drug Alcohol Depend. 2025. PMID: 40580890 Free PMC article. Clinical Trial.
BACKGROUND: Previous trials showed mirtazapine reduces methamphetamine use. The present study determined the influence of mirtazapine treatment on the acute effects of methamphetamine. ...Mirtazapine and infusions of methamphetamine, alone and combined, were …
BACKGROUND: Previous trials showed mirtazapine reduces methamphetamine use. The present study determined the influence of mirtazap …
388 results